07/23/2021 1:56 PM
Updated 07/23/2021 1:57 PM
In Buenos Aires there are
who hope to complete their vaccination scheme against the coronavirus. They are people who were inoculated with the first dose of
at least twelve weeks ago and are awaiting the arrival of the
second component of this vaccine.
This Friday a response from the Russian government was known regarding the world crisis that generates the delay in delivery, after the letter that transpired on Thursday and was sent by the presidential adviser Cecilia Nicolini. The Kremlin spokesman, Dmitri Peskov, admitted the delays, assured that he will fulfill the contracts with Argentina but
clarified that the priority is to supply his country.
Therefore, in this context, the option of
Combining with doses from other laboratories
grows as the most viable alternative to complete the schemes.
Both the City and the Province advance with their studies, and
the results would be in the first days of August
It is clear that the situation has
the health authorities in the AMBA on alert
, where clinical trials aim to verify the effectiveness and safety of using Sinopharm and AstraZeneca as a second component.
According to the City's open data, there are
who were inoculated with first doses of Sputnik V; of these,
197,601 received second doses
. On Monday, July 12, the last flight arrived from Russia (with 550 thousand components two) and the Buenos Aires jurisdiction received, on Wednesday, July 14, a total of 34,800 doses of that shipment.
In the City, the vaccine changeability trial
started on July 7.
After a week, the Ministry of Health reported that none of the 180 people who voluntarily participated had
abnormal adverse effects.
After the second week, the situation remains the same, which is an indication of good news: "Everything is still normal and the volunteers continue to
show no infrequent adverse effects
. During Thursday,
the first blood sample
was taken from all
. Next week the second and last will be taken, "they explained to
The Vaccine Combination Study in the City began July 7, and results may be due the first week of August.
Photo: Guillermo Rodríguez Adami
With both blood draws,
the amount of antibodies
developed with this combination and the neutralization power achieved will be determined. The samples are sent to the Muñiz Hospital and the University of Buenos Aires. And there could be results
the first days of August
In the first instance, if the combination of vaccines is equivalent to the current values, then it will be good news. According to the National Ministry of Health, with the second doses applied, the Sputnik V vaccine reduces the risk of death by 93.3% in people over 60 years of age, AstraZeneca by 88.8% and Sinopharm by 84%. Regarding the last two, other studies were known that confirm the coverage against the Delta variant - worrying for its high contagiousness - that is advancing in the world and is already in the country, with
29 cases detected
; still without community circulation.
In the Province of Buenos Aires, according to the information shared by the health area with
, they are also making progress with the trial. In this case,
with 900 volunteers
. A week has passed since second doses of AstraZeneca, Sinopharm and Sputnik V were applied. "So far we have not registered
any adverse effect
outside of what is expected from the application of any of the vaccines.
In 30 days we will have the first processed results
, that is say that in 40 days we will be able to have the preliminary results, "they reported.
As in the City, volunteers are people with and without comorbidities.
Province used the experiences carried out in
Spain, England, Germany and Scotland
as a reference for the design of the trial
In the case of the trial carried out by the City, the
180 people were divided into three groups
and were given second doses of AstraZeneca, Sinopharm and Sputnik V. Both the health personnel who administer the vaccines and the volunteers
know what the
is. vaccine that is inoculated.
The volunteers are all
over 21 years of age
and must have had the first dose of Sputnik-V more than 30 days ago and have not received any other vaccines in a period of 15 days. To the surprise even of the City,
6,000 people signed up
to participate in the study.
Will vaccines be added to the tests?
So far, those approved in Argentina are Sputnik V, AstraZeneca and Sinopharm.
As the European Medicines Agency (EMA) authorized the use of Moderna's vaccine in boys between 12 and 17 years old, and in principle it would be applied among those with comorbidities, adding it to the tests is not ruled out, especially considering that more doses may arrive and that the Argentine State signed an agreement with the laboratory for
the purchase of millions of vaccines by 2022.
The City's vaccine combination study started without adverse effects among volunteers
Fernán Quirós, on the health passport: "It is an instrument to evaluate, but it is not yet time for this type of measure"